December 18, 2017 / 2:10 PM / a month ago

BRIEF-La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401

Dec 18 (Reuters) - La Jolla Pharmaceutical Co:

* INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below